COST-EFFECTIVENESS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS

被引：0
|
作者：
Olasupo, O. [1 ]
Matino, D. [1 ]
Iorio, A. [1 ]
Blackhouse, G. [1 ]
Xie, F. [1 ]
Tarride, J. E. [1 ]
机构：
[1] McMaster Univ, Hamilton, ON, Canada
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE476
引用
收藏
页码：S428 / S428
页数：1
相关论文
共 50 条
  • [41] Budget Impact of Emicizumab for Routine Prophylaxis of Bleeding Episodes in Patients With Hemophilia A With Inhibitors
    Watanabe, Alexandre Hikiji
    Lee, Shaun Wen Huey
    Chai-Adisaksopha, Chatree
    Lim, Ming Y.
    Chaiyakunapruk, Nathorn
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 28 : 7 - 13
  • [42] Peri-operative hemostatic management of tooth extraction in patients with hemophilia A, with and without inhibitors, receiving emicizumab prophylaxis
    Yagyuu, Takahiro
    Furukawa, Shoko
    Zaizen, Miki
    Yata, Sachiko
    Imada, Mitsuhiko
    Nogami, Keiji
    Kirita, Tadaaki
    HAEMOPHILIA, 2023, 29 (01) : 172 - 179
  • [43] Maintaining Perioperative Hemostasis in Patients with Severe Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis
    Zimowski, Karen L.
    Batsuli, Glaivy M.
    Reding, Mark T.
    Rana, Jatin
    Callaghan, Michael U.
    Tickle, Kelly
    Meeks, Shannon L.
    Sidonio, Robert F., Jr.
    BLOOD, 2018, 132
  • [44] Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors
    McCary, Isabella
    Guelcher, Christine
    Kuhn, Jan
    Butler, Regina
    Massey, Gita
    Guerrera, Michael F.
    Ballester, Lance
    Raffini, Leslie J.
    BLOOD, 2019, 134
  • [45] Use of Emicizumab in Patients with Hemophilia a with and without Inhibitors: A Single Center Experience
    Giuffrida, Gaetano
    Nicolosi, Daniela
    Condorelli, Annalisa
    Markovic, Uros
    Di Raimondo, Francesco
    BLOOD, 2021, 138
  • [46] EMICIZUMAB IN PEDIATRIC PATIENTS WITH HEMOPHILIA A WITH AND WITHOUT INHIBITORS - EXPERIENCE OF A PORTUGUESE CENTRE
    Pestana, J. S. G.
    Peixoto, C.
    Camara, C.
    Correia, C. J.
    Felix, J.
    Pires, F.
    Pereira, A.
    Rodrigues, F.
    Afonso, P.
    Rocha, E.
    Catarino, C.
    HAEMOPHILIA, 2023, 29 : 107 - 107
  • [47] Immune tolerance induction for hemophilia A patients with inhibitors: A cost-effectiveness analysis.
    Colowick, AB
    Bohn, R
    Avorn, JL
    Ewenstein, BM
    BLOOD, 1998, 92 (10) : 553A - 553A
  • [48] Management of Joint Replacement in Hemophilia a with Inhibitors during Emicizumab Prophylaxis
    Santagostino, Elena
    Mancuso, Maria Elisa
    Novembrino, Cristina
    Boscolo, Massimo Anzoletti
    Clerici, Marigrazia
    Pasta, Gianluigi
    Solimeno, Luigi Piero
    Peyvandi, Flora
    BLOOD, 2017, 130
  • [49] Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors
    Kim, Sung Eun
    Kim, Ji Yoon
    Park, Jeong A.
    Lyu, Chuhl Joo
    Hahn, Seung Min
    Han, Jung Woo
    Park, Young Shil
    BLOOD RESEARCH, 2024, 59 (01)
  • [50] EMICIZUMAB IS COST-SAVING FOR FINNISH HEMOPHILIA A PATIENTS WITH FACTOR VIII INHIBITORS
    Viita, A. M.
    Conejero, Prada E.
    Laine, J.
    VALUE IN HEALTH, 2023, 26 (12) : S98 - S98
12345